multrys Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Multrys, and what generic alternatives are available?
Multrys is a drug marketed by Am Regent and is included in one NDA. There are three patents protecting this drug.
This drug has six patent family members in six countries.
The generic ingredient in MULTRYS is cupric sulfate; manganese sulfate; selenious acid; zinc sulfate. One supplier is listed for this compound. Additional details are available on the cupric sulfate; manganese sulfate; selenious acid; zinc sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Multrys
Multrys was eligible for patent challenges on April 30, 2023.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for multrys?
- What are the global sales for multrys?
- What is Average Wholesale Price for multrys?
Summary for multrys
| International Patents: | 6 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for multrys |
| What excipients (inactive ingredients) are in multrys? | multrys excipients list |
| DailyMed Link: | multrys at DailyMed |
Pharmacology for multrys
| Drug Class | Copper Absorption Inhibitor Paramagnetic Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
| Physiological Effect | Decreased Copper Ion Absorption |
US Patents and Regulatory Information for multrys
multrys is protected by three US patents and one FDA Regulatory Exclusivity.
Patents protecting multrys
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NEONATAL AND PEDIATRIC PATIENTS WEIGHING LESS THAN 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting multrys
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | MULTRYS | cupric sulfate; manganese sulfate; selenious acid; zinc sulfate | SOLUTION;INTRAVENOUS | 209376-003 | Jun 30, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Am Regent | MULTRYS | cupric sulfate; manganese sulfate; selenious acid; zinc sulfate | SOLUTION;INTRAVENOUS | 209376-003 | Jun 30, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Am Regent | MULTRYS | cupric sulfate; manganese sulfate; selenious acid; zinc sulfate | SOLUTION;INTRAVENOUS | 209376-003 | Jun 30, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Am Regent | MULTRYS | cupric sulfate; manganese sulfate; selenious acid; zinc sulfate | SOLUTION;INTRAVENOUS | 209376-003 | Jun 30, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for multrys
See the table below for patents covering multrys around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20230058047 | 미량 원소 조성물, 그 제조 및 사용 방법 | ⤷ Sign Up |
| Australia | 2021300384 | Trace element compositions, methods of making and use | ⤷ Sign Up |
| European Patent Office | 4175615 | COMPOSITIONS D'OLIGO-ÉLÉMENTS, LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION (TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE) | ⤷ Sign Up |
| China | 116096423 | 微量元素组合物、制备方法及应用 (Microelement composition, preparation method and application) | ⤷ Sign Up |
| Canada | 3186578 | COMPOSITIONS D'OLIGO-ELEMENTS, LEURS PROCEDES DE FABRICATION ET D'UTILISATION (TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
